Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2004
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapyMauro Zaccarelli, Carlo Federico Perno, Federica Forbici, et al.Current HIV Research|July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patientsAnnalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2010
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimensValentina Svicher, Claudia Alteri, Anna Artese, et al.Infectious Diseases and Therapy|March 19, 2026
Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study)Roberta Gagliardini, Alessandro Caioli, Marisa Fusto, et al.Antiviral Therapy|February 6, 2004
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapyBruno Christian Ciancio, Maria Paola Trotta, Patrizia Lorenzini, et al.The Journal of Antimicrobial Chemotherapy|September 16, 2021
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced diseaseYagai Bouba, Daniele Armenia, Federica Forbici, et al.AIDS Research and Human Retroviruses|February 3, 2009
Dynamics of NRTI resistance mutations during therapy interruptionMaria Trignetti, Tobias Sing, Valentina Svicher, et al.The New Microbiologica|July 18, 2006
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapyMaria Mercedes Santoro, Valentina Svicher, Caterina Gori, et al.Antiviral Therapy|April 26, 2003
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutationMauro Zaccarelli, Carlo Federico Perno, Federica Forbici, et al.The Journal of Antimicrobial Chemotherapy|September 6, 2011
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencingClaudia Alteri, Maria Mercedes Santoro, Isabella Abbate, et al.Pageof 6